Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + docetaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Ipilimumab + docetaxel is a combination therapy used in oncology, particularly studied for advanced prostate cancer and other solid tumors. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4), thereby enhancing antitumor immune responses by blocking inhibitory signaling on T cells. Docetaxel is a taxoid antineoplastic agent that binds to the β-subunit of tubulin, stabilizing microtubules and preventing their depolymerization, which disrupts cell division and leads to cancer cell death. This combination has been evaluated in clinical trials for hormone-refractory prostate cancer and other malignancies[1][2][5][6].
- Other names
- None
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ipilimumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + docetaxel.